Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21413937 | 0.86 | CHRM2 (0.49) | SMN1; SMN2L3MBTL1CHRM2CETPKDM4E | |
| SCHEMBL24065677 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1AHRCHRM2RAB9A | |
| SCHEMBL19441058 | 0.79 | TAAR1 (0.50) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL19879719 | 0.76 | CYP19A1 (0.41) | SMN1; SMN2L3MBTL1CHRM2 | |
| SCHEMBL18427298 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1CHRM2KDM4E | |
| SCHEMBL19916767 | 0.75 | ALDH1A1 (0.36) | SMN1; SMN2L3MBTL1AHRCHRM2HDAC6 | |
| SCHEMBL12803075 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1CHRM2HDAC6 | |
| SCHEMBL25054047 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1AHRCHRM2RAB9A | |
| SCHEMBL13077728 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1AHRCHRM2MEN1 | |
| SCHEMBL27800482 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1AHRCHRM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | SMN1; SMN2 1161/4885L3MBTL1 3669/4885AHR 417/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | SMN1; SMN2 1161/4885L3MBTL1 3669/4885AHR 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.